Roche Holding (SWX:ROP) Wins FDA Clearance, Is It Fully Priced?
Roche Holding (SWX:ROP) has seen fresh attention after the U.S. FDA granted 510(k) clearance for its cobas BV/CV molecular assay. This clearance expands the company’s diagnostics menu in vaginal and broader sexual health testing.
See our latest analysis for Roche Holding.
Alongside the new cobas BV/CV assay, Roche Holding’s share price is at CHF364.70, with a 30-day share price return of 9.92% and a 1-year total shareholder return of 51.19%, indicating that momentum has been building despite mixed recent earnings.
If this kind of diagnostics and healthcare news has your attention, it can be a good time to see what else is moving in the sector through 128 healthcare AI stocks
After a 51.19% 1 year total return and a 30 day surge of almost 10%, Roche Holding now trades roughly in line with the average analyst target, yet screens at a large intrinsic discount. Is the market’s caution misplaced or sensible given recent earnings softness?
Most Popular Narrative: 3.2% Overvalued
The most followed narrative on Roche Holding puts fair value at CHF353.34, slightly below the CHF364.70 last close. That small gap contrasts with the much larger intrinsic discount flagged by some quantitative screens and sets up a very different story to the one implied by the recent share price surge.
Roche is a high-quality, cash-generative pharma leader with:
✅ Strong fundamentals:
• $80B revenue scale
• ~$26B EBITDA
• ~30% margins
✅ Attractive profile:
• Defensive and dividend (~3%)
• Deep pipeline with multiple catalysts
⚠️ Constraints:
• Moderate growth versus biotech
• Clinical execution risk
The fair value call in this narrative leans heavily on Roche Holding’s scale, its margin profile and a long list of late stage assets. Want to see how the revenue growth, profit trajectory and future earnings multiple are woven together to justify that only slightly higher valuation than today’s price? The full narrative sets out the cash flow story behind the number and how much of the CHF353.34 hinges on the pipeline versus the existing business.
Result: Fair Value of CHF353.34 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Roche Holding’s story can shift quickly if late stage trial results disappoint or if biosimilars pressure the CHF62.96b revenue and CHF12.34b net income base.
Find out about the key risks to this Roche Holding narrative.
Another View On Roche Holding’s Value
The user narrative pegs Roche Holding at CHF353.34, which suggests the stock is slightly overvalued against the CHF364.70 share price. Our DCF model tells a very different story. It puts fair value at CHF887.39, which is a very large gap and implies a wide margin to current pricing. Which signal should investors treat as more reliable right now?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Roche Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 248 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With mixed signals on Roche Holding’s valuation and sentiment split between caution and optimism, it helps to move quickly and test the data yourself. To see how the key positives and concerns balance out in one place, review the 4 key rewards and 1 important warning sign
Looking for more investment ideas beyond Roche Holding?
If Roche Holding has sharpened your focus, do not stop here. Use the Simply Wall St Screener to spot other opportunities before they move out of reach.
- Target potential mispricings by reviewing companies that appear attractively valued through the 248 high quality undervalued stocks.
- Strengthen your income stream by assessing reliable payers in the 444 dividend fortresses.
- Increase your comfort level by focusing on companies with steadier profiles using the 298 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com